NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TLSI

TriSalus Life Sciences Inc

Jul 14 • 03:43PM ET

4.98

Dollar change +0.09
Percentage change 1.84	%

Healthcare • Medical Devices • USA • NASD

Peers: CRSP NTLA FATE IMTX EDIT BLUE SGMO ADAP CELU SLDB

| Held by: VXF VTI IWM IWN IWC IWO RSSL UWM URTY ITWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	58.16%	Shs Outstand	32.27M	Perf Week	0.40%
Market Cap	189.12M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.25%	Shs Float	15.89M	Perf Month	-5.14%
Enterprise Value	209.24M	PEG	-	EPS next Q	-0.21	Inst Own	8.08%	Short Float	3.46%	Perf Quarter	-10.27%
Income	-30.31M	P/S	5.88	EPS this Y	37.75%	Inst Trans	9.54%	Short Ratio	7.19	Perf Half Y	4.18%
Sales	32.14M	P/B	-	EPS next Y	78.69%	ROA	-117.01%	Short Interest	0.55M	Perf YTD	-0.60%
Book/sh	-1.06	P/C	14.55	EPS next 5Y	-	ROE	-	52W High	6.04 -17.55%	Perf Year	-6.21%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	- -175.42%	ROIC	-	52W Low	3.50 42.29%	Perf 3Y	-49.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	83.34%	Volatility	4.88% 6.32%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.51	EPS Y/Y TTM	53.73%	Oper. Margin	-99.01%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	85.03%	Profit Margin	-94.31%	RSI (14)	45.25	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.14	EPS Q/Q	35.35%	SMA20	-3.82%	Beta	0.50	Target Price	11.31
Payout	-	Debt/Eq	-	Sales Q/Q	41.97%	SMA50	-4.78%	Rel Volume	0.12	Prev Close	4.89
Employees	110	LT Debt/Eq	-	Earnings	May 15 BMO	SMA200	0.72%	Avg Volume	76.51K	Price	4.98
IPO	Feb 08, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-77.60% 1.44%	Trades		Volume	8,956	Change	1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Initiated	Lake Street	Buy
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$10
Nov-11-24	Initiated	ROTH MKM	Buy	$11
Oct-25-24	Initiated	Northland Capital	Outperform	$12.50
Sep-16-24	Initiated	Oppenheimer	Outperform	$10
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Jun-23-25 05:30PM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure (Business Wire) -5.37%
Jun-04-25 08:00AM	TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System (Business Wire)
May-30-25 07:00AM	TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire) -8.76%
May-16-25 03:01PM	TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-15-25 08:10AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance (Business Wire)
May-12-25 07:15PM	OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised) (Zacks)
04:30PM	TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call (Business Wire)
07:45AM	OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-08-25 06:45PM	TerrAscend Corp. (TSNDF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.31%
08:00AM	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results (Business Wire)
Apr-10-25 11:33AM	VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? (Zacks)
Apr-09-25 08:47AM	TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Mar-30-25 08:02AM	TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks (Seeking Alpha)
02:02PM	Loading…
Mar-27-25 02:02PM	TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:40AM	TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 08:00AM	TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav Infusion System Mapping (Business Wire)
Mar-06-25 08:00AM	TriSalus Life Sciences Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model" (Business Wire)
Feb-03-25 04:05PM	TriSalus Life Sciences Announces Key Appointments to Board of Directors (Business Wire)
08:00AM	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed (Business Wire)
Jan-23-25 08:00AM	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call (Business Wire) +5.31%
Jan-10-25 08:30AM	TriSalus Life Sciences announces publication of pre-clinical data (TipRanks) +7.95%
Jan-09-25 08:00AM	TriSalus Life Sciences Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres to Liver Tumors using Pressure-Enabled Drug Delivery (PEDD) via the TriNav Infusion System (Business Wire)
Jan-08-25 08:00AM	TriSalus Announces Leadership Changes (Business Wire) -7.18%
Nov-14-24 08:00AM	TriSalus Reports Q3 2024 Financial Results and Provides Business Update (Business Wire) -10.89%
Nov-13-24 07:27AM	TriSalus Life Sciences Inc (TLSI) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-11-24 07:00AM	TriSalus Life Sciences Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav Infusion System to U.S. Veterans with Liver Cancer (Business Wire) +5.91%
Nov-07-24 07:00AM	TriSalus Life Sciences Launches TriNav LV Infusion System and TriGuide Guiding Catheters, Expanding Portfolio of PEDD Devices for Improved Tumor Treatment (Business Wire)
08:00AM	Loading…
Oct-31-24 08:00AM	TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call (Business Wire)
Oct-14-24 04:05PM	TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-26-24 07:00AM	TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board (Business Wire)
Sep-23-24 07:00AM	TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD Method via the TriNav Infusion System (Business Wire) -6.70%
Sep-14-24 01:52AM	TriSalus Life Sciences Inc (TLSI) CEO Buys Shares (GuruFocus.com)
Aug-15-24 08:00AM	TriSalus Reports Q2 2024 Financial Results and Business Update (Business Wire)
Aug-01-24 07:00AM	TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call (Business Wire)
Jul-01-24 04:00PM	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation (Business Wire) -5.07%
Jun-26-24 05:45PM	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire)
Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67% +5.82%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)
Feb-21-23 07:00AM	TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business (Business Wire)
Dec-07-22 09:26PM	MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders (GlobeNewswire)
Nov-14-22 04:24PM	Colorado biotech company to go public via SPAC merger (American City Business Journals)
Mar-14-22 02:32PM	Robotic surgery company Memic pulls out of SPAC merger (American City Business Journals)
Mar-10-22 08:11AM	MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination (GlobeNewswire)
Jan-06-22 08:00AM	Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021 (PR Newswire)
Dec-30-21 03:00PM	A look at the South Florida tech companies that were acquired or went public in 2021 (American City Business Journals)
Oct-07-21 09:16AM	Is MedTech Acquisition Corporation (NASDAQ:MTAC) Popular Amongst Institutions? (Simply Wall St.)
Sep-09-21 06:00AM	Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation (PR Newswire)
Sep-03-21 09:25AM	Moore Kuehn Encourages FRSG, MTAC, SLCR, and ADF Investors to Contact Law Firm (GlobeNewswire)
Aug-19-21 12:32PM	Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal (PR Newswire)
Aug-13-21 05:49PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of MedTech Acquisition Corporation (Nasdaq - MTAC) (ACCESSWIRE)
08:07AM	Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination (PR Newswire)
Jun-02-21 04:05PM	MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-19-21 01:02PM	Robotics Firm Memic Is in Talks to Go Public Via SPAC (Bloomberg)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cox Bryan F.	Chief of Research	May 19 '25	Sale	5.18	4,764	24,678	119,415	May 21 05:33 PM
Devlin Jodi	Chief of Clinical Operations	May 19 '25	Sale	5.18	4,764	24,678	52,764	May 21 05:31 PM
Marshak Richard	Chief Commercial Officer	May 19 '25	Sale	5.18	6,597	34,172	69,101	May 21 05:30 PM
Stevens Jennifer	Chief Regulatory Officer	May 19 '25	Sale	5.18	8,704	45,087	77,640	May 21 05:27 PM
Young James Emmett	Chief Financial Officer	Feb 05 '25	Buy	5.65	6,000	33,900	30,000	Feb 06 06:09 PM
Szela Mary T	CEO AND PRESIDENT	Jan 30 '25	Buy	5.28	5,010	26,453	444,259	Jan 31 05:54 PM
Szela Mary T	CEO AND PRESIDENT	Jan 29 '25	Buy	5.03	5,030	25,301	439,249	Jan 31 05:54 PM
Szela Mary T	CEO AND PRESIDENT	Jan 27 '25	Buy	5.42	4,826	26,157	429,503	Jan 29 06:15 PM
Szela Mary T	CEO AND PRESIDENT	Jan 28 '25	Buy	5.12	4,716	24,146	434,219	Jan 29 06:15 PM
Murphy Sean	Chief Manuf, Strategy&Bus Dev.	Jan 27 '25	Buy	5.31	15,000	79,650	182,732	Jan 29 06:13 PM
Murphy Sean	Chief Manuf, Strategy&Bus Dev.	Jan 28 '25	Buy	5.17	15,000	77,550	197,732	Jan 29 06:13 PM
Young James Emmett	Chief Financial Officer	Jan 27 '25	Buy	5.40	24,000	129,600	24,000	Jan 29 06:03 PM
Cox Bryan F.	CHIEF SCIENTIFIC & MANUFACT.	Oct 05 '24	Sale	4.44	314	1,394	86,382	Dec 19 06:09 PM
Frankenius Equity AB	10% Owner	Dec 17 '24	Buy	3.97	62,972	249,999	6,230,748	Dec 19 06:03 PM
Desai Arjun JJ	Director	Dec 10 '24	Sale	3.69	30,000	110,700	247,127	Dec 12 05:40 PM
Arjun Desai	Board of Directors	Dec 10 '24	Proposed Sale	4.50	30,000	135,000		Dec 10 04:06 PM
Wahlstrom Mats	Director	Nov 22 '24	Buy	4.55	5,000	22,750	15,727	Nov 25 05:53 PM
Wahlstrom Mats	Director	Nov 21 '24	Buy	4.44	8,687	38,570	10,727	Nov 22 07:11 PM
Wahlstrom Mats	Director	Nov 20 '24	Buy	4.16	2,040	8,486	2,040	Nov 22 07:11 PM
Szela Mary T	CEO AND PRESIDENT	Sep 12 '24	Buy	5.20	7,520	39,104	377,382	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 13 '24	Buy	4.97	7,295	36,255	384,677	Sep 13 05:43 PM
Szela Mary T	CEO AND PRESIDENT	Sep 10 '24	Buy	4.97	5,000	24,850	369,862	Sep 12 07:06 PM
Martin George Kelly	Director	Aug 28 '24	Sale	5.50	9	50	247,176	Sep 10 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience